Soluble IL-6R in plasma cell dyscrasias

Leukemia and Lymphoma

Volumn 26, Issue 5-6, 1997, Pages 489-495

  Smith, Stephen R ^a   Morgan, Lynn ^b  

^a TORBAY HOSPITAL   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

IL 6; Multiple myeloma; Plasma cell disorders; sIL 6R

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

B LYMPHOCYTE; BLOOD LEVEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030700873     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709050885     Document Type: Review

References (69)

1. Van de Poel, H. W., Coebergh. J. W. W. and Hillen, H. F. P. (1995). Malignant transformation of monoclonal gammopathy of undetermined significance among patients of a community hospital in South-eastern Netherlands. Br J. Haem., 91, 121-125.
2. Kyle, R. A. (1993) Benign monoclonal gammopathy: after 20-35 years of follow up. Mayo. Clinic. Proc., 68, 26-36.
3. Kyle, R. A. (1994). Why better prognostic factors for multiple myeloma are needed Blood, 83, 1713-1716.
4. Kishimoto, T (1989) The biology of interleukin-6. Blood, 74, 1-10.
5. Kishimoto, T., Akira, S., Narazaki, M. and Taga, T. (1995) Interleukin-6 family of cytokines and gp130. Blood, 86, 1243-1254.
6. Hirano, T., Yasukawa, K., Hauda, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwanura, S., Nakajima, K., Koyama, K., Iwamatsu, A., Tsunasawa, S., Sakiyama, F., Matsui, H., Takahara, Y., Taniguchi, T. and Kishimoto, T. (1986). Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature, 324, 73-75.
7. Klein, B., Zhang, X.-G., Lu, Z.-Y. and Bataille, R. (1995). Interleukin-6 in human multiple myeloma. Blood, 85, 863-872.
8. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A. and Kishimoto, T. (1988). Autocrine generation and requirement of BSF-2/IL-6 for multiple myelomas. Nature, 332, 83-85.
9. Klein, B., Zhang, X.-G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. and Bataille, R. (1989). Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by Interleukin-6. Blood, 73, 517-526.
10. Anderson, K. C., Jones, R. M., Morimoto, C. Leavitt, P. and Barut, B. A. (1989). Response patterns of purified myeloma cells to hematopoietic growth factors. Blood, 73, 1915-1924.
11. Nilsson, K., Jernberg, H. and Petterson, M. (1990). IL-6 as a growth factor for multiple myeloma cells- A short overview. Curr. Top. Micro. Imm., 166, 3-12.
12. Klein, B., Zhang, X.-G., Jourdan, M., Portier, M. and Bataille, R. (1990). Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. Curr. Top. Micr. Imm., 166, 23-31.
13. Gaillard, J. P., Bataille, R., Brailly, H., Zuber, C., Yasuka, K., Altal, M., Maruo, N., Taga, T., Kishimoto, T. and Klein, B. (1993). Increased and stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur. J. Immunol., 23, 820-824.
14. Uckun, F. M. (1990). Regulation of human B-cell ontogeny. Blood, 76, 1908-1923.
15. Kincade, P. W., Lee, G., Pietrangeli, C. E., Hayashi, S.-I. and Gimble, I M. (1989) Cells and molecules that regulate B lymphopoiesis in bone marrow. Ann. Rev. Immunol., 7, 111-143.
16. Kincade, P. W. (1991). Molecular interactions between stromal cells and B lymphocyte precursors. Semin. Immunol., 3, 379-390.
17. Berek, C. (1992). The development of B cells and the B-cell repertoire in the microenvironment of the germinal centre. Immunol. Rev., 126, 519-524.
18. Liu, Y.-I., Johnson, G. D., Gordon, J. and Maclennan, I. C. M. (1992). Germinal centres in T-cell dependent antibody responses. Immunol Today, 13, 17-21.
19. Banchereau, J. and Rousset, F. (1992). Human B lymphocytes: Phenotype, proliferation and differentiation. Adv. Immunol., 52, 125-261.
20. Huilbert, D. M., Cancro, M. P., Scherle, P. A., Nordan, R. P., Van Snick. J., Gerhard, W. and Rudikoff, S. (1989). T cell derived IL-6 is differentially required for antigen-specific antibody secretion by primary and secondary B cells J. Immunol., 143, 4019-4024.
21. Raynal, M. C., Liu, Z. Y., Hirano, T., Mayer, L., Kishimoto, T. and ChenKiang, S (1989) Interleukin 6 induces secretion of IgG1 by coordinated transcriptional activation and differential mRNA accumulation. Proc. Natl. Acad. Sc. U.S.A., 86, 8024-8028.
22. Murakami, M., Hibi, M., Nakagawa, N., Nakagawa, T., Yasukawa, K., Yamanishi, K., Taga, T. and Kishimoto, T. (1993). IL-6 induced homodimerisation of gp130 and associated activation of a tyrosine kinase. Science, 260, 1808-1810
23. Macmillan, R., Longmire, R. L., Yelenosky, R., Lang, J. E., Heath, V. and Craddock, C. G. (1972). Immunoglobulin synthesis by human lymphoid tissues: normal bone marrow as a major site of IgG production. J. Immunol., 109, 1386-94
24. Tew, J. G., DiLosa, R. M., Burton, G. F., Kosco, M. H., Kupp, L. I., Masuda, A. and Szakal, A. K. (1992). Germinal centres and antibody production in bone marrow. Immunol. Rev., 126, 99-112.
25. Roldan, E., Rodriguez, C., Navas, G., Parra, C. and Brieva, J. A. (1992). Cytokine network regulating terminal maturation of human bone marrow B cells capable of spontaneous and high rate Ig secretion in vitro. J. Immunol., 149, 2367-2371.
26. Muraguchi, A., Hirano, T., Tang, B., Horii, Y., Nakajima, K. and Kishimoto, T. (1988). The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differential of B cells. J. Exp. Med., 167, 332-344.
27. Roldan, E., Garcia-Pardo, A. and Brieva, J. A (1992). VLA-4 fibronectin interaction is required for the terminal differentiation of human bone marrow cells capable of spontaneous and high rate Ig secretion. J. Exp. Med., 175, 1739-1747.
28. Asaoku, H., Kawano, M., Iwato, K., Tanabe, O., Tanaka, H., Hirano, T., Kishimoto, T. and Kuramoto, A. (1988). Decrease in BSF-2/IL-6 in advanced cases of multiple myeloma. Blood, 72, 429-432.
29. Kawano, M., Tanaka, H., Ishikawa, H., Nobuyoshi, M., Iwato, K., Asaoku, H., Tanabe, O. and Kuramoto, A. (1989). Interlekin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood, 73, 2145-2148.
30. Zhang, X. G., Klein, B. and Bataille, R (1989). Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma Blood, 74, 11-13.
31. Zhang, X.-G., Bataille, R., Widjenes, J. and Klein, B. (1992). Interleukin-6 dependence of advanced malignant plasma cell dyscrasis. Cancer, 69, 1373-1376.
32. Billadeau, D., Ahmann, G., Griepp, P. and Van Ness, B. (1993). The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant cell. J. Exp. Med., 178, 1023-1031
33. Bakkus, M. H. C., Van Riet, L., Van Camp, B. and Thielmans, K. (1994). Evidence that the clonogenic cell in multiple myeloma originates from a preswitched but somatically mutated cell. Br. J. Haematol. 87, 68-74.
34. Bakkus, M. H. C., Van Riet, L., De Greef, C., Van Camp, B. and Thielmans, K. (1995). The clonogenic precursor cell in multiple myeloma. Leukemia and Lymphoma, 18, 221-229.
35. Omede, P., Boccarado, M., Fusaro, A., Gallone, G. and Pileri, A. (1993). Multiple myeloma 'early' plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. Br. J. Haematol., 85, 504-513.
36. Joshua, D., Petersen, A., Brown, R., Pope, B., Snowdon, L. and Gibson, J. (1996). The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Br. J. Haematol., 94, 76-81.
37. Tanabe, O., Kawano, M., Tanaka, H., Iwato, K., Asaoku, H., Ishikawa, H., Nobuyoshi, M., Hirano, T., Kishimoto, T. and Kuramoto, A. (1989). BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. Am. J. Hematol., 31, 258-262.
38. Pelliniemi, T.-T., Irjala, K., Manila, K., Pulkki, K., Rajamaki, A., Tienhara, A., Laakso, M. and Lahtiten, R. (1995). Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood, 85, 765-771.
39. Bataille, R., Jourdan, M., Zhang, X.-G and Klein, B. (1989). Serum levels of interleukin-6, a potent myeloma growth factor as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Invest., 84, 2008-2001.
40. Reibnegger, G., Krainer, M., Herold, M., Ludwig, H., Wachter, H. and Huber, H. (1991). Predictive value of interleukin-6 and neoptrin in patients with multiple myeloma Cancer Res., 51, 6250-6253.
41. Tienhaara, A., Pulkki, K., Mattila, K., Irjala, K and Pelliniemie, T.-T. (1994). Serum immunoreactive interleukin-6 and C-reactive protein in patients with multiple myeloma at diagnosis. Br. J. Haem., 86, 391-393.
42. Smith, S. and Morgan, L. (1994). Immunoreactive Interleukin-6 and C-reactive protein in plasma cell disorders. Br. J. Haem., 87, 883-884.
43. 2 microglobulin, and C-reactive protein What is the best combination for prognosis? Blood, 82, 3507-3508.
44. Bataille, R., Barlogie, B., Lu, Z. Y., Rossi, J. F., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J. and Klein, B. (1995). Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86, 685-91.
45. Heinrich, P. C., Castell, J. W. and Andus, T. (1990). Interleukin-6 and the acute phase response. Biochem. J., 265, 621-636.
46. Baumann, H. and Gauldie, J. (1994). The acute phase response. Immunol. Today, 15, 74-80.
47. Yamasaki, K., Taga, T., Hirata, H., Yawata, Y., Kawanishi, Y., Seed, B., Taniguchi, T., Hirano, T. and Kishimoto, T. (1988). Cloning and expression of the human interleukin 6 (BSF-2/IFNb2) receptor. Science. 241, 825-828.
48. Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T. and Kishimoto, T. (1990). Molecular cloning and expression of an IL-6 signal transducer. gp130. Cell, 63, 1149-1157.
49. Nakajima, K., Matsuda, T., Fujitani, Y., Hirotada, K., Yamanaka, Y., Nakae, K., Takeda, T. and Hirano, T. (1995) Signal transduction through IL-6 receptor. Involvement of multiple protein kinases, stat factors, and a novel H7-sensitive pathway. Ann. N. Y. Acad. Sci., 762, 55-70.
50. Heaney, M. L. and Golde, D. W. (1996). Soluble cytokine receptors. Blood, 87, 845-857.
51. Taga, T., Narazaki, M., Yasukawa, K., Saito, T., Miki, D., Hamaguchi, M., Davis, S., Shoyab, M., Yancoupoulos, G. D. and Kishimoto, T. (1992). Functional inhibition of hematopoietic-and neurotropic-cytokines (LIF, OM and CNTF) by blocking IL-6 signal transducer, gp 130. Proc. Natl. Acad. Sci. U.S.A, 89, 10998-11001.
52. Rose-John, S., Ehlers, M., Grotzinger, J. and Mullberg, J. (1995). The soluble interleukin-6 receptor. Ann. N. Y. Acad. Sci., 762, 207-220.
53. Honda, M., Yamamoto, S., Cheng, M., Yasukawa, K., Suzuki, H., Saito, T., Osugi, Y., Tokunaga, T. and Kishimoto, T. (1992). Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection. J. Immunol., 148, 2175-2180.
54. Rose-John, S. and Heinrich, P. C. (1994). Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J., 300, 281-290.
55. Narazaki, M., Yasukawa, T., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G. D., Taga, T. and Kishimoto, T. (1993). Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130 Blood, 82, 1-7.
56. Akira, S., Taga, T. and Kishimoto, T. (1993) Intedeukin-6 in biology and medicine. Adv. Immunol., 54, 1-78.
57. Mullberg, J., Scooltink, H., Stoyan, T., Gunther, M., Graeve, L., Buse, G., Mackiewicz, A., Heinrich, P. C. and Rose-John, S (1993). The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol., 23, 473-480.
58. Mullberg, J., Dittrich, E., Graeve, L., Gerhart, C., Yasukawa, K., Taga, T., Kishimoto, T., Heinrich, P. C. and Rose-John, S. (1993). Differential shedding of the two subunits of the interleukin-6 receptor. FEBS LETTERS, 332, 174-178.
59. Lust, J. A., Donovan, K. A., Kline, M. P., Greipp, P. R., Kyle, R. A. and Maihle, N. J. (1992). Isolation of a mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine., 4, 96-100.
60. May, L. T., Ndubuisi, M. I., Patel, K. and Garcia, D. (1995). Interleukin-6 chaperones in blood. Ann. N. Y. Acad. Sci., 621, 20-128.
61. Ohtani, K., Ninomiya, H., Hasegawa, Y., Kobayashi, T., Kojima, H., Nagasawa, T. and Abe, T. (1996). Clinical significance of elevated soluble interluekin-6 receptor levels in the sera of patients with plasma cell dyscrasias Br. J. Haem., 91, 116-120
62. Smith, S. R. and Morgan, L. (1996). Clinical significance of elevated soluble interleukin 6 receptor levels in patients with plasma cell disorders. Br. J. Haem., 92, 766-767.
63. Pulkki, K., Pelliniemi, T.-T., Rajamaki, A., Tienhaara, A., Laakso, M. and Lahtinen, R. (1996). Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br. J. Haem., 92, 370-374.
64. Greipp, P. R., Gaillard, J. P., Kalish, L. A., Oken, M. M., Miller, A. M., Kyle, R. A. and Klein, B. (1993). Independent prognostic value for serum soluble interleukin-6 receptor (sIL-6R) in Eastern Cooperative Oncology Group (ECOG) myeloma trial E9487. Proc. Am. Soc. Clin. Oncol., 12, 404.
65. Joshua, D. E., Brown, R. D. and Gibson. J. (1994). Prognostic factors in myeloma: What they tell us about the pathophysiology of the disease. Leukaemia and Lymphoma, 15, 375-381.
66. Smith, S. R., Auerbach, B. and Morgan, L. (1996). Serum neural cell adhesion molecule in multiple myeloma and other plasma cell disorders. Br. J. Haem., 92, 67-70.
67. Ong, F., Kaiser, U., Seelen, P. J., Hermans, J., Wijermans, P. W., de Kieviet, W., Jacques, G. and Luin-Nelemans, J. C. (1996). Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinaemias due to other causes. Blood, 87, 712-716.
68. 2-microglobulin predict survival independent of thymidme kinase and C-reactive protein in multiple myeloma. Blood. 81, 3382-3387.
69. 2-microglobulin produce a simple and powerful myeloma staging system. Blood, 80, 733-737.